Related Experiment Video
Updated: Mar 2, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics
Leslie Z Benet1, Hsin-Fang Wu1
1Department of Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco 94143, California.
Journal of Pharmaceutical Sciences
|May 16, 2017
Summary
This study found no ethnic differences in rosuvastatin pharmacokinetics among individuals with specific genetic profiles (OATP1B1 and BCRP wild-type). Further research is needed, but current evidence suggests no significant disparities in drug metabolism based on ethnicity in this population.
Area of Science:
- Pharmacology
- Genetics
- Clinical Research
Background:
- Rosuvastatin pharmacokinetics can vary significantly between ethnic groups.
- Genetic factors, including OATP1B1 and BCRP, are implicated in drug metabolism.
- Previous studies have suggested ethnic differences in rosuvastatin response.
Purpose of the Study:
- To investigate potential ethnic differences in rosuvastatin pharmacokinetics between Asian and white populations.
- To determine if genetic variations in OATP1B1 and BCRP influence these pharmacokinetic differences.
Main Methods:
- Prospective clinical study comparing rosuvastatin pharmacokinetics in Asian and white subjects.
- Analysis of subjects who are wild-type for the OATP1B1 and BCRP genes.
- Virtual clinical study analysis and review of previous retrospective studies.
Main Results:
- No significant ethnic difference in rosuvastatin pharmacokinetics was observed in wild-type OATP1B1 and BCRP subjects.
- Virtual clinical study analysis supported the prospective findings.
- Retrospective analyses lacked sufficient data to confirm ethnic differences in wild-type subjects.
Conclusions:
- The study suggests no ethnic differences in rosuvastatin pharmacokinetics for individuals with wild-type OATP1B1 and BCRP.
- Further confirmatory studies are warranted due to potential limitations in statistical power.
- Existing evidence does not conclusively support ethnic disparities in rosuvastatin metabolism for this genetic profile.
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
273
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
273
01:27Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
01:27Principles of Pharmacogenetics: Types of Genetic Variants
60
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
60
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
01:16Drug toxicity: Idiosyncratic Reactions
67
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
67
01:24Dosage Regimen: Individualization
232
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
232